5月25日，据CDE官网消息，上海齐鲁锐格医药研发有限公司联合申请药品“RGT-274-CR胶囊”，获得临床试验默示许可，受理号CXHL2500266。
公示信息显示，药品“RGT-274-CR胶囊”适应症：成人肥胖/超重患者的体重管理。
上海齐鲁锐格医药研发有限公司，成立于2018年，位于上海市，是一家以从事科技推广和应用服务业为主的企业。企业注册资本4000万人民币，实缴资本3711万人民币。
通过天眼查大数据分析，上海齐鲁锐格医药研发有限公司知识产权方面有商标信息21条，专利信息5条，此外企业还拥有行政许可10个。
主要股东信息显示，上海齐鲁锐格医药研发有限公司由RG Therapeutics Limited持股100%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.